PMID- 15809450
OWN - NLM
STAT- MEDLINE
DCOM- 20050628
LR  - 20220316
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 23
IP  - 16
DP  - 2005 Jun 1
TI  - Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of 
      poor outcome.
PG  - 3773-9
AB  - PURPOSE: Although most classical Hodgkin's lymphoma (CHL) patients are cured, a 
      significant minority fails primary therapy and may die as a result of their 
      disease. Age, stage, and other basic clinical and laboratory parameters, which 
      comprise the International Prognostic Score (IPS), are used at diagnosis to 
      predict outcome. To date, there is no consensus on biologic markers that add 
      value to these parameters. PATIENTS AND METHODS: We evaluated 107 CHL patients 
      for bcl-2, p53, and p21 expression by immunohistochemistry using tissue 
      microarrays and correlated the results with outcome. The median follow-up of the 
      79 surviving patients was 6.8 years. RESULTS: Univariate analysis showed that age 
      > or = 45 years, stage III or IV, and IPS > or = 3 were associated with a poor 
      failure-free survival (FFS) and overall survival (OS). bcl-2 was expressed in 26% 
      of patients and was associated with poor FFS and a trend for OS. p53 expression 
      in combination with lack of p21 expression was not associated with outcome. 
      Multivariate analysis showed that three factors were independently associated 
      with both FFS and OS: age > or = 45 years, stage III or IV, and bcl-2 expression. 
      Using these three parameters, a scoring system was devised that stratified 
      patients into three risk groups (with zero, one, or two to three of these risk 
      factors) and a progressively worse FFS and OS (P < .001). CONCLUSION: Expression 
      of bcl-2 in CHL is a useful, independent prognostic marker and can be used in 
      association with clinical parameters to identify newly diagnosed patients with a 
      good, intermediate, or poor prognosis.
FAU - Sup, Stephen J
AU  - Sup SJ
AD  - Department of Clinical Pathology, L-11, Cleveland Clinic Foundation, 9500 Euclid 
      Ave, Cleveland, OH, USA.
FAU - Alemany, Carlos A
AU  - Alemany CA
FAU - Pohlman, Brad
AU  - Pohlman B
FAU - Elson, Paul
AU  - Elson P
FAU - Malhi, Serena
AU  - Malhi S
FAU - Thakkar, Snehal
AU  - Thakkar S
FAU - Steinle, Roxanne
AU  - Steinle R
FAU - Hsi, Eric D
AU  - Hsi ED
LA  - eng
PT  - Journal Article
DEP - 20050404
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Cell Cycle Proteins/*metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p21
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Hodgkin Disease/*metabolism/pathology
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Microarray Analysis
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-2/*metabolism
MH  - Survival Rate
MH  - Tumor Suppressor Protein p53/*metabolism
EDAT- 2005/04/06 09:00
MHDA- 2005/06/29 09:00
CRDT- 2005/04/06 09:00
PHST- 2005/04/06 09:00 [pubmed]
PHST- 2005/06/29 09:00 [medline]
PHST- 2005/04/06 09:00 [entrez]
AID - JCO.2005.04.358 [pii]
AID - 10.1200/JCO.2005.04.358 [doi]
PST - ppublish
SO  - J Clin Oncol. 2005 Jun 1;23(16):3773-9. doi: 10.1200/JCO.2005.04.358. Epub 2005 
      Apr 4.